Ultrasensitive Sepsis Diagnostics
Sepsis
Development/CommercializationActive
Key Facts
About DIANA Biotechnologies
DIANA Biotechnologies is a diversified, venture-backed biotech firm leveraging its proprietary DIANA technology platform to serve the diagnostics and life science research markets. Its core business spans four segments: life science reagents (including a high-potency RNase inhibitor and reverse transcriptase), custom oligonucleotide synthesis, monoclonal antibody development, and drug discovery services like kinase inhibitor profiling. Having established itself as a major COVID-19 test producer in Czechia, the company is now targeting global expansion with its portfolio of PCR solutions and high-value research services.
View full company profileOther Sepsis Drugs
| Drug | Company | Phase |
|---|---|---|
| Point of care multiplex sepsis test | EDX Medical | Launching |
| VB-001 | VST Bio | Pre-clinical |
| SIXTIDE | Sepsia Therapeutics | Pre-clinical |
| Injectable Melatonin (IPR-490) | Pharmamel | Phase 2 |
| EXO‑CD24 | Nano24med | Preclinical |